financetom
Business
financetom
/
Business
/
Paramount's co-CEO Robbins to step down, memo shows
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Paramount's co-CEO Robbins to step down, memo shows
Aug 6, 2025 4:09 PM

Aug 6 (Reuters) - Brian Robbins, who helped grow the

Paramount+ streaming service, is stepping down as Paramount

Global's ( PARAA ) co-CEO, according to a memo seen by Reuters on

Wednesday, following the completion of its merger with Skydance

Media.

David Ellison, the CEO of Skydance, will lead the new

company as chief executive after the merger is completed by

August 7.

"The company is in exceptionally capable hands with David

Ellison and the incoming team from Skydance," Robbins said in

the memo.

Robbins, who joined the company in 2017, was appointed

co-CEO in April last year, along with George Cheeks and Chris

McCarthy, with the three collectively succeeding Bob Bakish.

McCarthy's departure was reported last month, while Cheeks

will remain with the company as its chair of media, overseeing

its broadcast and cable television business.

Robbins was named CEO of Nickelodeon in 2018, and became the

chief of Paramount Pictures in 2021.

As CEO of Paramount Pictures, Robbins has overseen 17 number

one releases at the box office and has overseen franchises

including "Sonic the Hedgehog," "A Quiet Place," and "Mission:

Impossible."

After the deal closes, the company is expected to be

structured into three primary business segments - studios,

direct-to-consumer and TV media.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Pantages Capital Acquisition Announces Business Combination With MacMines Austasia
BRIEF-Pantages Capital Acquisition Announces Business Combination With MacMines Austasia
Nov 19, 2025
Nov 19 (Reuters) - Pantages Capital Acquisition Corp ( PGAC ) : * PANTAGES CAPITAL ACQUISITION CORPORATION ANNOUNCES BUSINESS COMBINATION WITH MACMINES AUSTASIA PTY LTD. * PANTAGES CAPITAL ACQUISITION CORP ( PGAC ) -TRANSACTION VALUES TARGET AT USD$180 MILLION * PANTAGES CAPITAL ACQUISITION CORP ( PGAC ): UPON CLOSING OF DEAL, SHARES OF COMBINED COMPANY ARE EXPECTED TO TRADE ON...
Nanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcare IT, Accelerating U.S. Rollout of AI Solutions
Nanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcare IT, Accelerating U.S. Rollout of AI Solutions
Nov 19, 2025
PETACH TIKVA, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ( NNOX ) , an innovative medical imaging technology company, today announced that the parties have agreed on the terms and conditions pursuant to which Nanox will acquire VasoHealthcare IT Inc. (“VHC IT”) from Vaso Corporation (“Vaso”) , subject to certain conditions. This transaction is intended to accelerate...
AI Infrastructure Acquisition Corp. to Ring the NYSE Opening Bell
AI Infrastructure Acquisition Corp. to Ring the NYSE Opening Bell
Nov 19, 2025
LAS VEGAS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- AI Infrastructure Acquisition Corp. (the “Company”) , a newly organized blank check company incorporated as a Cayman Islands exempted company and led by Chief Executive Officer Michael Winston, announced today that it is celebrating its October 2025 initial public offering by ringing the New York Stock Exchange (“NYSE”) Opening Bell. The NYSE Opening Bell...
EyePoint Gets Positive Recommendation for Wet AMD Trials From Safety Committee
EyePoint Gets Positive Recommendation for Wet AMD Trials From Safety Committee
Nov 19, 2025
08:29 AM EST, 11/19/2025 (MT Newswires) -- EyePoint Pharmaceuticals ( EYPT ) said Wednesday that an independent Data Safety Monitoring Committee has recommended that its ongoing pivotal phase 3 program evaluating Duravyu for the treatment of wet age-related macular degeneration continue as planned without any modifications to the protocol. Topline data from the trials is expected starting in mid-2026, the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved